ARCHIVES

FDA Oncology Division Invites Advocates To Play Early Role In Cancer Drug Review.

This article is from The Cancer Letter archive.

Vol. 27 No. 12 | March 23, 2001

Download PDF Visit The Full Archive

Related Articles

FDA Committee Can’t Find “Reasonable” Evidence Alkylating Agent Clinical Use Is Carcinogenic

September 10, 1976

Vermont Cancer Center’s NCI Core Grant Renewed.

May 11, 2001

NCI To Fund 160 P01s FY91, About same As Last Year; Considering New ‘Interactive’ R01

June 21, 1991

BRCA2 Carriers Reduced BC Risk By Prophylactic Surgery

June 30, 2006

House Passes Bill Giving FDA Authority Over Tobacco Products

April 10, 2009

Second-Generation CML Drugs Show Promise For Frontline

December 26, 2008